Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2021.

The report highlights that during the quarter the Company enrolled the first patient into the MagSense® HER2 Test Reagent Phase 1 Breast Cancer Study and progress with additional sites for recruiting into the study, as well as the signing of a collaboration with Patrys Limited aimed to improve brain tumor imaging.

Imagion received a $2.6 million R&D tax incentive in relation to 2020 R&D activities, an increase on the $2.2 million received in the prior year.

Read our Appendix 4C here: https://www.asx.com.au/asxpdf/20210730/pdf/44yvd0j4r5l6l7.pdf